This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

* Agreement comes ahead of annual meeting set for June 16 * Genzyme to appoint Steven Burakoff, Eric Ende directors * Icahn to withdraw slate of four nominees to board * Genzyme's shares rise 0.1 ...

CAMBRIDGE, Mass. and SOUTH PLAINFIELD, N.J., July 17 /PRNewswire- FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and PTC Therapeutics, Inc. (PTC) today announced an exclusive global collaboration to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items in the FDA's complete response ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

Ending nearly a year-long saga, Genzyme (NASDAQ:GENZ) agreed to a sweetened buyout from France’s Sanofi-Aventis (NYSE:SNY) on Wednesday that values the U.S. biotech giant at just north of $20 billion.

Talk about innovation, technology and good jobs in Central Massachusetts and there’s a good chance you’re talking about biotechnology. Talk about biotechnology for more than a few minutes and there’s ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme Corporation (Nasdaq: GENZ) announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy ...

Genzyme Genetics is a leading, nationwide provider of high quality genetic testing and genetic counseling services for physicians and their patients. With laboratories and counseling facilities ...

Dana Alexander, program director for Genzyme, shows off the company's new $170 million manufacturing facility in Framingham during a tour of the site on Tuesday. BRANDON BUTLER While Cambridge-based ...

The consolidation in the biotechnology industry continued Monday as Genzyme Corp. agreed to pay $600 million in cash to acquire a Bay Area company, SangStat Medical Corp., and its lucrative drug to ...